THE gC1q RECEPTOR, HIV-1 gp120 REGION BINDING THERETO, AND RELATED PEPTIDES AND TARGETING ANTIBODIES

Abstract: Disclosed are immunogens and peptides based on the binding site of gC1q-R for HIV-1 gp120, and immunogens and peptide based on the binding site of HIV-1 gp120 for gC1q-R. The sequence of the gC1q-R binding site for gp120 is shown in SEQ ID NO.: 2. The sequence of HIV-1 gp120 binding site for gC1q-R is shown in SEQ ID NO.: 3. Also disclosed are antibodies and binding molecules to all such immunogens and peptides, and inducing the endogenous production of such antibodies.

Description: THE gClq RECEPTOR, HIV-1 gpl20 REGION BINDING THERETO, AND RELATED PEPTIDES AND TARGETING ANTIBODffiS Field of the Invention The invention is related to (1) peptides which bind to HIV-1 gpl20 and which are based on the gClq receptor (gClq-R), as well as antibodies to such peptides; (2) HIV-1 gpl20 related peptides which bind to gClq-R, and antibodies to such peptides. Background of the Invention Clq is a component of the Cl complex of the classical complement pathway (R.B. Sim and K.B.M. Reid, Immunology Today 1991 ; 12:307- 311). The biological functions of Clq are diverse, including initiation of the complement cascade for opsonization and cytolysis, and mediation of several different functions depending on the cell types expressing the Clq receptor. Clq enhances FcR and CR1 -mediated phagocytosis in monocytes/macrophages (D.A. Bobak et al., Eur. J. Immunol. 1988; 18:2001-2007; D.A. Bobak et al., J. Immunol. 1987; 138: 1150-1156), stimulates immunoglobulin production by B cells (K.R. Young et al., J. Immunol. 1991 ; 146:3356-3364), activates platelets to express IIb/3 3 integrins, P-selectin, and procoagulant activity (E.I.B. Peerschke et al. , J. Exp. Med. 1993; 178:579-587; E.I.B. Peerschke et al., J. Immunol. 1994; 152:5896-5901), activates tumor cytotoxicity of macrophages (R.W. Leu et al. , 7. Immunol. 1990; 144:2281-2286), and exerts anti-proliferative effects on T cell growth (A. Chen et al., /. Immunol. 1994; 153: 1430-1440). A 33 kilodalton (kD) receptor, designated gClq-R, which binds to the globular head of Clq molecules has been recently identified, cloned and sequenced (B. Ghebrehiwet et al., J. Exp. Med. 1994; 179: 1809-1821; E.I.B. Peerschke et al., J. Immunol. 1994; 152:5896-5901; A. Chen et al., /. Immunol. 1994; 153: 1430-1440). Another 60 kD receptor, designated cClq-R, binds to the amino-terminal collagen-like region of Clq (B. Ghebrehiwet, Behring Inst. Mitt. 1989; 84:204-215; A. Chen et al., J. Immunol. 1994; 153: 1430-1440). Based on the detection of gClq-R mRNA by polymerase chain reaction (PCR) amplification and gClq-R protein expression by immunochemical methods, this receptor was found to exist on a large number of different cell types, e.g. B cells, T cells, monocytes/macrophages, neutrophils, eosinophils, fibroblasts, platelets, endothelial cells, liver cells, neural cells and smooth muscle cells. It was not known, however, that gClq-R binds to HIV-1 gpl20 and neutralizes the infectivity of HIV-1. It is well established that the CD4 antigen, which is expressed mainly on the surface of the helper/inducer T cells, is the primary receptor for HIV-1 gpl20 (P.J. Maddon et al. , Cell 1986; 47:333-385; J.S. McDougal et al. , Science 1986; 231:382-385). In addition to the CD4 + T cells, HIV-1 can bind to and infect a number of other cell types, such as monocytes/macrophages, B cells, colon epithelial cells and neuroglial cells, which express either undetectable or at most low levels of cell-surface CD4. Several alternative receptors have been suggested to be associated with HIV-1 infection of target cells, e.g. galactosylceramide (Gal-Cer) on the surface of human colon epithelial cells, Schwann cells, and oligodendrocytes (N. Yahl et al. , Virology 1994; 204:550-557; J.M. Harouse et al., Science 1991; 253:320-323), human immunoglobulin V H 3 gene products of IgM isotype (mol. wt. 950 kD) on B cells (L. Berberian et al., Science 1993; 261:1588-1591), CD26 (mol. wt. 110 kD) on activated T and B cells (C. Callebaut et al., Science 1993; 262:2045-2050), and a membrane-associated C-type lectin (mol. wt. 46 kD) mainly on macrophages (B.M. Curtis et al., Proc. Natl. Acad. Sci. USA 1992; 89:8356-8360). This invention was made in the course of research to find cellular binding proteins or receptors for HIV-1 gpl20 on non-CD4 expressing cells. To this end, lysates of CEM-SS cells (which are T cells expressing a high level of cell-surface CD4) obtained from P.J. Nara (AIDS Res. Hum. Retroviruses 1987; 3:283-302) and DAKIKI cells (which are CD4-negative B cells) obtained from American Type Culture Collection (Rockville, Maryland) were run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the separated proteins were transblotted onto nitrocellulose membranes for Western immunoblot assays. It was found that recombinant or HIV-1 -infected cell derived gpl20 reacted with a protein band of 32-33 kD in both CEM-SS and DAKIKI cell lysates, which was distinct from the 55 kD protein band reactive with anti-human CD4 monoclonal antibodies. In order to purify this novel gpl20-binding protein for identification by N-terminal amino acid sequencing, a large quantity of DAKIKI cell lysate was prepared. The gpl20-binding protein was partially purified by preparative electrophoresis using Prep Cell Model 491 (Bio-Rad Laboratories, Inc., Hercules, California). The sample was then run on 2- dimensional gel electrophoresis and blotted onto polyvinylidene difluoride (PVDF) membrane for Western immunoblotting to identify the gpl20- reacting protein spot and for N-terminal amino acid sequencing. It was determined that the sequence of the first fifteen amino acids at the N- terminus of the gpl20-reacting protein was identical to that of the protein previously identified as p32 (mol. wt. 32 kD), which was co-purified with a human pre-mRNA splicing factor by A.R. Krainer et al. (Cell 1991; 66:383-394) and B. Honore et al. (Gene 1993; 134:282-287). Further experiments revealed that DAKIKI cells can be stained by rabbit anti-p32 immunoglobulins which were generated by using purified E. coli expressed p32 as the immunogen, showing that p32 exists on the cell surface of DAKIKI cells. DAKIKI cells were also shown to bind recombinant HIV-1 gpl20, even though the cells do not express detectable CD4 on the cell surface by immunofluorescence methods. Taken together, these findings show that p32 is an alternative cell-surface binding protein for HIV-1 gpl20. Subsequently, it was determined that p32 has the same sequence as gClq-R (SEQ ID NO. : 1) (B.B. Ghebrehiwet et al., J. Exp. Med. 1994; 179:1809-1821). The precursor or pre-proprotein of gClq-R has 282 amino acids (a.a.), and the functional mature protein has 209 a.a.. This mature protein contains the peptidic portion between amino acid residue nos. : 74 (leucine) and 282 (glutamine), of SEQ ID NO.: 1. Mature gClq-R protein is highly charged and acidic. It has three potential N-glycosylation sites at amino acid positions: 114, 136 and 223. As a result, the apparent molecular weight of gClq-R in SDS-PAGE is 32 kD, instead of 24.3 kD as calculated from the amino acid composition. Since the mature protein has only one cysteine residue at position 186, there is no intrachain disulfide linkage within the protein. gClq-R is found in a wide variety of cell types, such as B cells, T cells, monocytes/macrophages, esosinophils, neutrophils, platelets, endothelial cells, fibroblasts, and liver cells. Inasmuch as gClq-R is associated with multiple immunological and physiological functions, the interaction between gClq-R and HIV-1 gpl20 may account for some of the immunological and physiological dysfunctions manifested by HIV-1 -infected individuals. It may also result in the known ability of HIV-1 to infect a wide variety of non-CD4 expressing human cells in different tissues and organs. Intervention in the interaction between gClq-R and HIV-1 gpl20 represents a new strategy in combating HIV-1 disease. Several inventions based on this intervention strategy are discussed below. Summary of the Invention The invention includes immunogens and peptides based on the binding site of gClq-R for HIV-1 gpl20, and immunogens and peptides based on the binding site of HIV-1 gpl20 for gClq-R. The sequence of the gClq-R binding site for gpl20 is shown in SEQ ID NO. : 2. The sequence of the HIV-1 gpl20 binding site for gClq-R is shown in SEQ ID NO.: 3. The invention also includes antibodies and binding molecules to all such immunogens and peptides, and inducing the endogenous production of such antibodies. Other aspects and embodiments of the invention are described further below. Brief Description of the Drawings Fig. 1 is a restriction map of the vector pT7-7 used to express in E. coli the full-length mature form of gClq-R (1-209 a.a.) and its three truncated forms. gClq-R (δl-57) represents gClq-R (58-209 a.a.), gClq-R(C) represents gClq-R (95-209 a.a.), and gClq-R(N) represents (1-94 a.a.). Fig. 2 shows the binding of HIV-1 gpl20 to gClq-R, as measured by ELISA. The Y axis represents the reactivity of HIV-1 gpl20 with gClq-R expressed as OD at 450 nm and the X axis is the concentration of HIV-1 gpl20 in solution. Fig. 3 A shows the neutralization of the infectivity of HIV- HUB by gClq -R in CEM-SS cells; where Vn is the mean number of syncytia in duplicate test wells, and Vo the mean number of syncytia in the duplicate control wells. Fig. 3B shows the neutralization of the infectivity HIV-IMN by gClq- R in CEM-SS cells; where Vn is the mean number of syncytia in duplicate test wells, and Vo the mean number of syncytia in the duplicate control wells. Fig. 3C shows the neutralization of the infectivity of HIV-IRF by gClq-R in CEM-SS cells; where Vn is the mean number of syncytia in duplicate test wells, and Vo the mean number of syncytia in the duplicate control wells. Fig. 4 shows the inhibition of fusion between HIV-lIIIB-infected H9 cells and CD4 + -HeLa cells by gClq-R. Fig. 5 shows the binding of purified E. coli expressed gClq-R to HIV- lIIIB-infected H9 cells as determined by flow cytometry. Fig. 6 shows the effect of Clq on HIV-1 gpl20 binding to gClq-R in ELISA. The line marked with filled circles represents Clq and the line marked with filled squares represents gClq-R. The Y axis represents the reactivity of gpl20 with gClq-R expressed as OD at 450 nm and the X axis is the concentration of Clq and gClq-R in solution. Fig. 7 shows the reactivity of HIV-1 gpl20 with different forms of E. coli expressed gClq-R as solid-phase antigen in ELISA. The line marked with filled squares represents the full-length mature form of gClq-R (1-209 a.a.). The line marked with filled circles indicates the truncated gClq-R (58-209 a.a.), representing gClq-R with deletion of the N-terminal 57 amino acids. The line marked with filled triangles represents the N-terminal construct, gClq-R (1-94 a.a.). The line marked with filled inverted triangles represents the C-terminal construct, gClq-R (95-209 a.a.). The Y axis represents the reactivity of HIV-1 gpl20 with the different forms of gClq-R expressed as OD at 450 nm and the X axis is the concentration of gpl20 in solution. Fig. 8 shows the binding of antibody 99-12-1 to the gClq-R peptide LM12DN. The line marked with filled squares represents the peptide LM12DN and the line marked with filled circles represents the peptide TD18EE. The Y axis represents the reactivity of 99-12- 1 with the peptides expressed as OD at 450 nm and the X axis is the concentration of 99-12-1 in solution. Fig. 9 shows the competition of gClq-R binding to HIV-1 gpl20 by anti- gClq-R monoclonal antibody 99-12-1. Fig. 10 shows the competition of HIV-1 gpl20 binding to gClq-R by anti- HIV-1 gpl20 antibodies G3-299 and 6205. The line marked with filled circles represents anti-HIV-1 gpl20 C4 region G3-299, the line marked with filled squares represents polyclonal sheep antibody 6205, which is specific against the HIV-1 gpl20 C5 region peptide (amino acid residue numbers of HXB2R: 497-511, SEQ ID NO.: 10), and the line marked with solid triangles represents recombinant soluble CD4 (rsCD4). Fig. 11 shows the reactivity of gClq-R with the HIV-1 gpl20 C4 region peptides RC12LT, TG12NN, and RC16GG. The line marked with solid triangles represents RC16GG, the line marked with solid circles represents TG12NN, and the line marked with solid squares represents RC12LT. The Y axis represents the reactivity of gClq- R with the peptides expressed as OD at 450 nm and the X axis is the concentration of gClq-R in solution. Making and Using the Invention A. gClq-R Peptides The complete nucleotide and deduced amino acid sequences of gClq-R are shown in SEQ ID NO.: 1. The recombinant gClq-R which was expressed in E. coli and used in the immunizations and other examples described below is the entire C-terminal segment starting from the leucine at amino acid residue number 74 in SEQ ID NO.: 1. This segment represents the soluble, mature protein of gClq-R which was characterized. The N-terminal segment may represent a hydrophobic membrane anchor in the pre-proprotein. The peptidic segment encompassing amino acid residue numbers 239 to 250 of SEQ ID NO.: 1 was identified as the active binding site for gpl20, based on the complete inhibition of gpl20 binding to gClq-R by an anti-gClq-R monoclonal antibody 99-12-1 (which binds to the peptide of SEQ ID NO.: 2) as discussed below under Example 10. The active binding site of gClq-R for gpl20 can be expressed as a distinct peptide (hereinafter "the gpl20 binding site"), or any longer peptide which includes the gpl20 binding site (such as, for example, the peptide representing the entire gClq-R sequence) (see Example 1 below), or the gpl20 binding site or such longer peptides can be linked to another protein such as keyhole limpet hemocyanin (KLH) or another carrier molecule which enhances its immunogenicity, or the gpl20 binding site can be bound to a peptide or molecule engendering an immunogenic configuration to enhance its immunogenicity, or a peptide which is structurally or immunologically equivalent to the gpl20 binding site can be used for the same purpose (all such peptides hereinafter referred to as the "gpl20 Binding Site Peptides"). The gpl20 Binding Site Peptides are useful for detecting or quantitating HIV-1 gpl20, HIV-1 virions or HIV-1 -infected cells in a diagnostic assay. Such a diagnostic assay can use a standard assay format, such as an enzyme-linked immunosorbent assay (ELISA). In an ELISA, the gpl20 Binding Site Peptides can be immobilized on inert solid matrices or magnetic beads, either directly or indirectly through a cross-linking agent or a specific binding agent. The biological fluid test samples are then incubated with the coated matrices. Free HIV-1 gpl20 molecules or HIV-1 virions bearing gpl20 molecules reactive with the gpl20 Binding Site Peptides will bind to the matrices. The bound HIV-1 gpl20 molecules or HIV-1 virions can then be detected with either monoclonal or polyclonal anti-HIV-1 antibodies, which can then be reacted with enzyme-linked secondary detecting antibodies for quantitation based on color reaction. Alternatively, the captured gpl20 or virions can be detected by other means, e.g. fluorescence, chemiluminescence, radioactivity counting, or PCR. The gpl20 Binding Site Peptides can also be used to detect and quantitate HIV-1 -infected cells in patient's blood samples or other specimens by either direct or indirect immunochemical procedures. For example, in one such assay, the infected cells are contacted with the gpl20 Binding Site Peptides and then labeled with antibodies binding thereto. These detecting antibodies can be directly or indirectly conjugated with a fluorescent probe. Immunofluorescence is then detected by viewing the cells under a fluorescence microscope, or by flow cytometric methods. Alternatively the gpl20 Binding Site Peptides can be labeled directly with enzymes, radionuclides, fluorescent probes or biotin. The labeled peptides bound to the cells can then be detected correspondingly by well established methods. The gpl20 Binding Site Peptides, or any derivative products such as conjugates with a toxin (e.g. ricin A, diphtheria toxin, Pseudomonas aeruginosa exotoxin A, pokeweed antiviral protein), a high-energy radionuclide (e.g. iodine-131 , indium-I l l , and yttrium-90), a cytotoxic drug (e.g. doxorubicin), a cell membrane-active molecule (e.g. phospholipase, complements, and saponin), or as a microcarπer (such as liposomes) can also be used in treatment of HIV-1 disease or prevention of HIV-1 infection. The peptide corresponding to the entire sequence of the mature protein of gClq-R has been shown to neutralize the in vitro infectivity of several divergent strains of HIV-1 and to inhibit syncytium formation between CD4-positive cells and cells infected with HIV-IIIIB. See Examples 5 and 6 below. Administration of the gpl20 Binding Site Peptides would also be expected to bind to gpl20 and neutralize HIV-1, and also to prevent HIV-1 from infecting other cells through cell-to-cell fusion (syncytium formation). Such administration could serve as a treatment for HIV-1 disease or it could be administered prophylactically, either before or immediately after exposure to HIV-1, to prevent or inhibit HIV-1 infection. In prophylactic use, it could be administered to high-risk groups, such as intravenous drug users and health care workers, as a preventive measure. Alternatively, it could be used following a needle-stick injury to prevent infection, or just before or immediately after birth to prevent mother-to- baby HIV-1 transmission. The gpl20 Binding Site Peptides can be conjugated to solid matrices. These modified matrices can be used extracorporeally to remove free HIV-1 virions or HIV-1 infected cells from HIV-1 -infected individuals in order to reduce viral loads. B. Antibodies to gClq-R Peptides Monoclonal or polyclonal antibodies against gClq-R can be readily made with well known techniques as described below in Example 2. Such monoclonal antibodies could be generated using monovalent or polyvalent gClq-R, or the gpl20 Binding Site Peptides, as immunogens. The gClq-R peptide (or the gpl20 Binding Site Peptides) can also be used to screen for the hybridomas following immunization and fusion. Another alternative is to make immunogens using any of the gpl20 Binding Site Peptides or equivalent peptides having the ability to bind to the relevant part of the gpl20 C4 region in combination with one or more protein carriers. Preferred protein carriers are KLH, tetanus toxoid or Bacillus Calmette- Guerin (BCG). Recombinant protein antigens such as those from vaccinia virus, hepatitis B virus, adenovirus, or influenza virus can also be used. These carriers can be chemically conjugated to the gpl20 Binding Site Peptides, or the entire carrier-peptide can be expressed by a recombinant host cell. Polyclonal antibodies can be generated in animals (e.g. rodents, sheep, goats, guinea pigs, rabbits, and non-human primates) using the gpl20 Binding Site Peptides or equivalent peptides as immunogens (see Example 3 below). Monoclonal or polyclonal antibodies specific to the gpl20 binding site of gClq-R can also be generated by immunizing animals with deoxyoligonucleotides encoding the gpl20 Binding Site Peptides as DNA immunogens (J.J. Donnelly et al., J. Immunol. Meth. 1994; 176:145-152). The specific oligonucleotides encoding gClq-R can be constructed together with other expression vectors (e.g. vaccinia virus, hepatitis B virus, cytomegalovirus, retroviruses, or adenoviruses) for enhancing expression and gene targeting. Alternatively direct intramuscular injection, mechanical procedures such as high-velocity gold microprojectiles coated with DNA to transfect epidermis, or ex-vivo transfections by chemical (e.g. calcium phosphate) or electrical means, can be employed to insert the oligonucleotides into host cells for expression of antigens to induce specific antibody response. Such monoclonal or polyclonal antibodies have a number of uses. They can be used to detect cells which express the gClq-R receptor, such as B cells, T cells, monocytes/macrophages, neutrophils, eosinophils, fibroblasts, platelets, and endothelial and smooth muscle cells, using an immunofluorescence assay format or others, as described above. The monoclonal antibody 99-12-1 reactive with gClq-R has been shown to compete with gpl20 for binding to gClq-R (see experiments described under Example 11 below). Thus, they could also be used as a treatment for HIV-1 disease or, if administered prophylactically, either before or immediately after exposure to HIV-1 to prevent or inhibit HIV-1 infection. If used in treating HIV-1 disease or to prevent infection in humans, they would preferably be used either in the form of chimeric, humanized or human antibodies. Chimeric antibodies are produced by recombinant processes well known in the art, and have an animal variable region and a human constant region. Humanized antibodies have a greater degree of human peptide sequences than do chimeric antibodies. In a humanized antibody, only the complementarity determining regions (CDRs) which are responsible for antigen binding and specificity are animal derived and have an amino acid sequence corresponding to the animal antibody, and substantially all of the remaining portions of the molecule are human derived and correspond in amino acid sequence to a human antibody. See L. Riechmann et al. , Nature 1988; 332:323-327; G. Winter, United States Patent No. 5,225,539; C. Queen et al. , International Patent No. WO 90/07861. Human antibodies can be made by several different ways, including by use of human immunoglobulin expression libraries (Stratagene Corp. , La Jolla, California) to produce fragments of human antibodies (V H , V L , F v , Fd, Fab, or F(ab') 2 ), and using these fragments to construct whole human antibodies using techniques similar to those for producing chimeric antibodies. Human antibodies can also be produced in transgenic mice with a human immunoglobulin genome, which are produced by GenPharm International (Mountain View, California). The animals are immunized with the gpl20 Binding Site Peptides. Human antibodies against the gpl20 Binding Site Peptides can be found in vaccinees receiving the immunogens. Hybridomas or EBV-transformed B cell lines can be developed from the B cells of the donors. Human antibodies can also be generated by combinatorial library methodology (T.A. Collet et al., Proc. Natl. Acad. Sci. USA 1992; 89:10026-10030), using mRNA coding for the heavy and light chains of the anti-gpl20 binding site antibodies. These mRNAs can be obtained from the B cells of the vaccinees as described above. Alternatively, one can create single peptide chain binding molecules in which the heavy and light chain F v regions are connected (J.S. Huston et al. , Proc. Natl. Acad. Sci. USA 1983; 85:5879-5883). All of the wholly and partially human antibodies are less immunogenic than wholly murine monoclonal antibodies, and the fragments and single chain antibodies are also less immunogenic. All these types of antibodies are therefore less likely to evoke an immune or allergic response. Consequently, they are better suited for in vivo administration in humans than wholly animal antibodies, especially when repeated or long-term administration is necessary. Antibodies to the gpl20 Binding Site Peptides can be injected into animals (e.g. mice) to raise anti-idiotypic monoclonal antibodies. The anti- idiotypes may mimic the original antigen and thus can be used as immunogens to generate antibodies against the gpl20 binding site, or as gClq-R to block HIV-1 infection. C. HIV-1 gp!20 Peptides Binding to eClq-R A recombinant peptide having the sequence of amino acid residue nos. 444 to 459 of HIV-1 gpl20 of HXB2R strain, as shown in SEQ ID NO. : 3, was determined to bind to gClq-R by the method described below under Example 13. This peptidic segment is located in the gpl20 region designated C4 (C.K. Leonard et al., J. Biol. Chem. 1990; 265: 10373- 10382). This peptide is referred to hereinafter as "the gClq-R Binding Site Peptide". Such a peptide, or longer peptides containing this peptide or equivalent peptides with the ability to bind to gClq-R, could be used as immunogens to generate monoclonal or polyclonal antibodies which target such gpl20 region. A recombinant peptide having the sequence as shown in SEQ ID NO. : 3, or longer peptides including such peptides or equivalent peptides with the ability to bind to gClq-R, or other immunogens based on such peptides (for example, made by conjugating these peptides to preferred carrier proteins such as to KLH, tetanus toxoid or BCG, or including them as a part of an immunogenic structure such as a defective or attenuated forms of hepatitis B virus, adenovirus, or influenza virus) could be used as vaccines against HIV-1 as described above. These carriers can be chemically conjugated to the gpl20 Binding Site Peptides, or the entire carrier-peptide can be expressed from a recombinant host cell. When used as vaccines, they would generate antibodies endogenously, and the generated antibodies would bind to the gClq-R binding site of gpl20 and neutralize HIV-1 , or they will bind to HIV-1 -infected cells to inhibit viral transmission via cell-to-cell fusion or to kill infected cells by antibody dependent cellular cytotoxicity (ADCC) or complement mediated cytolysis (CMC). Monoclonal or polyclonal antibodies specific to the binding site of gpl20 for gClq-R can also be generated by immunizing animals with deoxyoligonucleotides encoding the gClq-R Binding Site Peptide as DNA immunogens (J.J. Donnelly et al., J. Immunol. Meth. 1994; 176: 145-152). The specific oligonucleotides encoding this portion of gpl20 can be constructed together with other expression vectors (e.g. vaccinia virus, hepatitis B virus, cytomegalovirus, retroviruses, or adenoviruses) for enhancing expression and gene targeting. Alternatively direct intramuscular injection, mechanical procedures such as high- velocity gold microprojectiles coated with DNA to transfect epidermis, or ex-vivo transfections by chemical (e.g. calcium phosphate) or electrical means, can be employed to insert the oligonucleotides into host cells for expression of antigens to induce specific antibody response. D. Antibodies to HIV-1 gp!20 Peptides Monoclonal antibodies against SEQ ID NO. : 3, representing the gClq-R Binding Site Peptide could be generated with conventional techniques by immunizing animals (such as rodents and non-human primates) with gpl20 or such peptides, or the above-described immunogens. Polyclonal antibodies can also be generated using well known techniques, as described above. Monoclonal or polyclonal antibodies to the gClq-R Binding Site Peptide (in the C4 region of gpl20) can also be generated in animals or humans with oligonucleotides encoding this region, or a longer region, as a DNA immunogen or vaccine as described above. These monoclonal or polyclonal antibodies can be used for detecting or quantifying HIV-1 gpl20, HIV-1 virions or HIV-1 -infected cells in a diagnostic assay. Such a diagnostic assay can use a standard assay format, such as an ELISA. The ELISA is constructed in a similar manner to that described above for the gpl20 Binding Site Peptides except that the anti- HIV-1 gpl20 antibodies - rather than these peptides - are immobilized on inert solid matrices or magnetic beads. The biological fluid test samples are then incubated with the coated matrices. HIV-1 gpl20 or HIV-1 virions bearing gpl20 molecules reactive with the antibodies will bind to the matrices. The bound virions or gpl20 can then be detected with other monoclonal or polyclonal anti-HIV-1 antibodies, which can then be reacted with enzyme-linked secondary detecting antibodies for quantitation based on color reaction. Alternatively, the captured gpl20 or HIV-1 virions can be detected by other means, e.g. fluorescence, chemiluminescence, or PCR. These antibodies can also be used to detect and to quantitate the HIV-1 -infected cells in patient blood samples by direct or indirect immunofluorescence procedures, as described above for the gpl20 Binding Site Peptides. The antibodies can also be labeled directly with enzymes, radionuclides, fluorescent probes or biotin. The labeled antibodies bound to the cells can then be detected by established methods. Antibodies against this gClq-R binding site in the C4 region of HIV- 1 gpl20 region could also potentially be used in treatment of HIV-1 disease or prevention of HIV-1 infection. They can be used individually or in combination with other anti-HIV-1 neutralizing antibodies, recombinant soluble CD4, anti-retro viral drugs or cytokines. Such antibodies would be expected to be neutralizing because once bound to gpl20, they should inhibit it from binding to gClq-R and thus preventing the subsequent infection of target cells. These antibodies would probably be in chimeric, humanized or human form when used for therapy or prevention of HIV-1 infection. The methods of generation of these forms of antibodies are described above. In addition, transgenic mice with a human immunoglobulin genome can be immunized with the gClq-R Binding Site Peptides in order to produce human antibodies. Alternatively, human antibodies against the C4 region of gpl20 can be found in HIV-1 -infected individuals or vaccinees receiving the gClq-R Binding Site Peptides containing immunogens. Hybridomas or EBV-transformed B cell lines can be developed from the B cells of these donors. Human antibodies can also be generated by the combinatorial library methodology (T.A. Collet et al. , Proc. Natl. Acad. Sci. USA 1992; 89: 10026-10030), using mRNA coding for the heavy and light chains of the anti-C4 antibodies. These mRNAs can be obtained from the B cells of HIV-1 -infected individuals or the vaccinees as described above. The monoclonal or polyclonal antibodies can be used to target cytotoxic agents to kill infected cells, either in the form of conjugates or microcarriers (such as liposomes). The conjugated agents can be, for example, toxins, cytotoxic drugs, membrane-active enzymes or chemicals, and high-energy radionuclides. The antibodies to the gClq-R binding site on gpl20 can be conjugated to solid matrices. These modified matrices can be used extracorporeally to remove free HIV-1 virions or HIV-1 -infected cells from HIV-1 -infected individuals in order to reduce viral loads. The antibodies to the gClq-R Binding Site on gpl20 can be modified by combining with another antibody with different specificity (e.g. to cell surface markers or HIV-1 antigens). Such bi-specific antibodies can be generating by either chemical conjugation (S.A. Kostelny et al., J. Immunol. 1992; 148:1547-1553; A. Mabondzo et al. , J. Inf. Dis. 1992; 166:93-99) or fusion of the two hybridomas (S.M. Chamow et al., J. Immunol. 1994; 153:4268-4280). Antibodies to the gClq-R Binding Site Peptides can be injected into animals (e.g. mice) to raise anti-idiotypic monoclonal antibodies. Anti- idiotypic monoclonal antibodies may mimic the original antigen used for generating the antibody targeted, and thus can be used as immunogens to generate antibodies against the gClq-R Binding Site. Exemplification of how to make and use the invention, and verification of its utility, appears below. Example 1 : Expression of the gClq-R Proteins in E. coli A. RNA isolation and cDNA preparation: Total RNA was isolated from 5 x 10° DAKIKI cells by the RNA-ZOL extraction method following the manufacturer's procedure (Biotecx, Houston, Texas). Ten micrograms of the RNA were used as a template for preparing the first strand of cDNA in a reverse transcription reaction mixture which contained 50 mM Tris- HC1 (pH 8.3) and 20 units of RNASIN (Promega, Madison, Wisconsin), 0.5 mM each of dATP, dTTP, dCTP and dGTP, 10 μM oligo dT, and 2 units of AMV reverse transcriptase (Gibco BRL, Gaithersburg, Maryland). The reaction was performed at 42 °C for 1 hour. B. PCR to amplify the gClq-R cDNA encoding the mature full- length gClq-R protein (from leucine at position 74 to glutamine at position 282 of SEQ ID NO.: 1). The sequences of the two primers used in the PCR were derived from the gClq-R cDNA gene (A.R. Krainer et al., Cell 1991; 66:383-394) with the Primer No. 1 having a Nde I and Primer No. 2 a Pst I restriction s ite s added . (Primer N o . 1 S EQ I D NO . : 4 TACATATGCTGCACACCGACGGAGAC; Primer No. 2 SEQ ID NO. : 5 GCCCTGCAGCATCTGTCTGCTCTA). The PCR reaction was carried out in 50 mM KC1, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 0.01 % gelatin, 0.2 mM each of dATP, dTTP, dCTP and dGTP, 0.5 mM of each of the primers, 2 μl of the reverse transcription reaction mixture, and 1 unit of Taq DNA polymerase (United States Biochemicals, Cleveland, Ohio). PCR was conducted at 94 °C (1 minute), 55 °C (2 minutes) and 72°C (2 minutes) for 40 cycles on the GeneAmp 9600 (Perkin Elmer, Norwalk, Connecticut). C. Construction of the gClq-R expression vector and expression of the full-length mature recombinant protein in E. coli. The gClq-R cDNA segment was cloned into the pT7-7 vector (United States Biochemicals) by double restriction enzyme Nde I and Pst I digestion (Fig. 1). The host E. coli strain was BL21. The cloned gene was under the control of the strong T7 promoter and was expressed upon induction by 1 mM IPTG. D. Expression of truncated gClq-R recombinant proteins. A recombinant gClq-R with its N-terminal portion truncated, designated gClq-R(C), was produced as shown in Fig. 1. The gene segment encoding the N-terminal portion was removed from the pT7- 7/gClq-R expression vector by EcoR I and BstX I restriction digestion. gCl-R(C) contains the peptidic segment between phenylalamine at position 168 and gluta ine at position 282 of SEQ ID. NO. : 1. The ends of the vector were blunted by T4 DNA polymerase and re-ligated by T4 DNA ligase. The peptide gClq-R(C) was expressed in BL21 cells in the same way as for the full-length gClq-R. A recombinant gClq-R with its C-terminal portion truncated, designated gClq-R(N), was produced as shown in Fig. 1. gClq-R(N) contains the peptidic segment between leucine at position 74 and asparagine at position 167 of SEQ ID NO. : 1. The gene segment encoding the C- terminal portion was removed from the pT7-7/gClq-R expression vector by BstX I and Pst I digestion. The ends of the vector were blunted by T4 DNA polymerase and re-ligated by T4 DNA ligase. The peptide gClq- R(N) was expressed in BL21 cells in the same way as for the full-length gClq-R. A recombinant gClq-R with its N-terminal 57 amino acids truncated, designated gClq-R(61-57) was produced as shown in Fig. 1. gClq-R (61-57) contains a peptidic segment between valine at position 131 and glutamine at position 282 of SEQ ID NO. : 1. The gene segment was first synthesized by PCR. The full-length gClq-R cDNA, the template, and two primers, Primer No. 2, SEQ ID NO.:5, and Primer No. 3 (SEQ ID NO. :6), having the sequence AAGAATTCCGGTCACTTTCAACATT, were used in the PCR. The reaction conditions for the PCR is the same as above except that the amplification cycles was reduced to 25. The PCR amplified DNA segment was cloned into the pT7-7 vector by sites EcoRI and Pst I. The peptide gClq-R(δl-57) was expressed in BL21 cells in the same way as the full-length gClq-R. E. Production and purification of gClq-R from E. coli. E. coli expressing gClq-R was cultured and harvested by sonification in Tris buffer. The lysate was centrifuged and the supernatant dialyzed against a buffer containing 20 mM HEPES, 0.1 M KCl, 0.5% glycerol, 0.2 mM EDTA and 1 mM dithiothreitol at pH 8.0. The dialyzed sample was loaded on a pre-equilibrated Fast Q ion-exchange column (Pharmacia Biotechnology, Piscataway, New Jersey). The bound proteins were eluted with a buffer containing 20 mM HEPES and 1 M KCl at pH 8.0. Fractions tested positive for gClq-R by SDS-PAGE and Western immunoblot for reactivity with recombinant gpl20 were collected. The pooled fractions were further purified on a Sephracryl 200 gel filtration column (Pharmacia Biotechnology). The purity of the final material was determined by SDS-PAGE and its binding activity with gpl20 by ELISA (see Example 4 below). Example" 2: Making Monoclonal Antibodies Against the eClq-R Peptide Male BALB/cJ mice (Jackson Laboratories, Bar Harbor, Maine) of 12 weeks old, were injected subcutaneously with 100 μg of purified E. coli expressed gClq-R in complete Freund's adjuvant (Difco Laboratories, Detroit, Michigan) in 200 μl of PBS. One month later, the mice were injected subcutaneously with 100 μg of gClq-R in incomplete Freund's adjuvant. Then one month later and three days prior to sacrifice, the mice were again injected subcutaneously with 100 μg of the same antigen in incomplete Freund's adjuvant. For each fusion, single cell suspensions were prepared from the spleen of an immunized mouse and used for fusion with Sp2/0 myeloma cells. 5 x 10 8 of the Sp2/0 cells and 5 x 10 8 spleen cells were fused in a medium containing 50% polyethylene glycol (M.W. 1450) (Kodak, Rochester, New York) and 5% dimethylsulfoxide (Sigma Chemical Co., St. Louis, Missouri). The cells were then adjusted to 1.5 x 10 5 of the spleen cells per 200 μl of the suspension in Iscove medium (Gibco, Grand Island, New York), supplemented with 10% fetal bovine serum, 100 units/ml of penicillin, 100 μg/ml of streptomycin, 0.1 mM hypoxanthine, 0.4 μM aminopterin, and 16 μM thy idine. Two hundred microliters of the cell suspension were added to each well of about twenty 96- well microculture plates. After about ten days culture supernatants were withdrawn for screening by ELISA with Immulon 1 microtest plates (Dynatech Laboratories, Alexandria, Virginia) pre-coated with 50 x 10 3 DAKIKI cells per well. DAKIKI cells were tested to express gClq-R abundantly on the surface. Briefly, wells of the microtest plates coated with dried DAKIKI cells were added with 200 μl of 5% BLOTTO (non-fat dry milk) in phosphate-buffered saline (PBS) to block the non-specific sites. An hour later, the wells were then washed with the buffer PBST (PBS containing 0.05% Tween 20). Fifty microliters of culture supernatant from each fusion well were collected and mixed with 50 μl of BLOTTO and then added to the individual wells of the microtest plates. After one hour of incubation, the wells were washed with PBST. The murine antibodies bound to the cells were then detected by reaction with horseradish peroxidase (HRP) conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania), diluted at 1 : 1 ,000 in BLOTTO. Peroxidase substrate solution containing 0.1 % 3 ' , 3 ' , 5', 5' tetramethyl benzidine (Sigma) and 0.0003% hydrogen peroxide was added to the wells for color development. The reaction was terminated by addition of 50 μl of 2 M H 2 SO 4 per well. The optical density (OD) at 450 nm of the reaction mixture was read with a BioTek ELISA reader (BioTek Instruments, Winooski, Vermont). The culture supernatants in those positive wells were also tested for reactivity with recombinant gClq-R in ELISA. Briefly, to wells of Immulon 2 (Dynatech Laboratories) microtest plates 50 μl of E. coli expressed gClq-R at 1 μg/ml was added overnight at room temperature. After the coating solution was removed by flicking of the plate, 200 μl of BLOTTO were added to each well for one hour to block the non-specific sites. The wells were then washed with PBST. The bound murine antibodies were detected as described above. The cells in those positive wells were cloned by limiting dilution. The clones were tested again for reactivity with gClq-R in the ELISA. The selected hybridomas were grown in spinner flasks and the spent culture supernatant collected for antibody purification by protein A affinity chromatography. One of the monoclonal antibodies so produced against gClq-R, 99-12-1, was tested to determine if it would compete with HIV-1 gpl20 for binding to gClq-R (see Example 11 below). Example 3: Making Polyclonal Antibodies Against gClq-R Two male New Zealand white rabbits, about fifteen weeks old, were immunized subcutaneously with 100 μg of purified E. coli expressed gClq- R in complete Freund's adjuvant (Difco Laboratories). Two weeks later they were injected again with the same amount of the antigen in incomplete Freund's adjuvant. The same immunization was repeated two weeks later. Sera were collected from the immunized animals and tested for reactivity with gClq-R in ELISA as described above except HRP conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories) at 1 :2,000 dilution in BLOTTO was used for detection of the bound antibodies. The animal showing the higher serological response was used for collecting serum. Polyclonal rabbit anti-gClq-R immunoglobulins were purified by an affinity column using gClq-R coupled Affigel 102 (BioRad Laboratories). Example 4: Binding of HIV-1 IIIB ED120 to E. coli Expressed gClα-R in ELISA Wells of Immulon 2 plates were coated with 100 μl of E. coli expressed gClq-R (5 μg/ml in 0.1 M sodium acetate buffer at pH 6) and incubated overnight at room temperature. After the wells were treated with the blocking buffer PBSTB (PBST containing 2% bovine serum albumin) for 1 hour at room temperature and rinsed with PBST, 100 μl of serially diluted baculovirus expressed HIV-IIIIB gpl20 (American Biotechnologies, Inc., Cambridge, Massachusetts) (from 2 μg/ml to 0.016 μg/ml) was added to the corresponding wells in duplicate for reaction for 1 hour at room temperature. The wells were then washed as before. The bound gpl20 was detected by the anti-HIV-1 gpl20 V3-domain murine monoclonal antibody BAT 123 conjugated with HRP at a dilution of 1 :2000. The antibody was tested to react with the peptidic segment in gpl20 (amino acid residue nos. of HXB2R strain: 308-322) as shown in SEQ ID NO. : 7, and also not to interfere with the binding between gClq-R and gpl20. One hundred microliters of the diluted conjugate were added to each well for reaction for 1 hour at room temperature. The wells were then washed, and 200 μl of the peroxidase substrate solution was added to each well for color development for 30 minutes. The reaction was stopped by addition of 50 μl of 2 M H 2 SO 4 , and OD measured by a BioTek ELISA reader at 450 nm. Specific reactivity is obtained by subtracting the OD of the test well with gpl20 added from that of the control wells without gpl20. The results are shown in Fig. 2, where it can be seen that as gpl20 concentration increases, the binding of gpl20 to a constant amount of immobilized recombinant gClq-R increases in a sigmoidal fashion. This shows a dose-dependent binding of gpl20 to gClq-R. Inasmuch as the anti- gpl20 V3 region antibody BAT123 is still able to react with gpl20 bound to gClq-R, it shows that the binding of gClq-R to gpl20 does not involve the V3 region of gpl20, as shown in SEQ ID NO. : 7. Example 5: HIV-1 Neutralization Assay To test the inhibitory activity of gClq-R on the infectivity of HIV-1 , a syncytium-forming microassay using CEM-SS cells as targets was performed as described by P.L. Nara et al. (AIDS Res. Hum. Retroviruses 1987; 3:283-302). Briefly, 50 μl of diluted E. coli expressed gClq-R was mixed with 50 μl viral culture supernatant containing 200 syncytium- forming units (SFUs) of HIV-IIIIB, HIV-IMN, or HIV-IRF, and incubated for 1 hour at room temperature. The mixtures were added into microculture wells containing 5 x 10 4 DEAE-dextran-treated CEM-SS cells, and the cell cultures were maintained in 5% CO 2 at 37 °C for three to four days. The syncytia were enumerated under an inverted microscope. The neutralizing activity was expressed as IC 50 , defined as the concentration required to achieve 50% inhibition of the infection (i.e. , Vn/Vo = 50%), where Vn is the SFU in the test wells and Vo is the SFU in the control wells without test antibodies. The results are shown in Figs. 3A, 3B and 3C. It can be seen that gClq-R neutralized HIV-IIIIB, MN, and RF with IC 50 of 4.3, 13.5, and 1.65 μg/ml, respectively. These neutralization data indicate that gClq-R can broadly inhibit the infectivity of divergent HIV-1 isolates. Example 6: Assay for Inhibitory Activity on Svncvtium Formation The effects of gClq-R on HIV-1 transmission via cell-to-cell fusion was studied using HIV-1 -infected H9 cells and CD4-expressing HeLa cells (HeLa-CD4 + ), which fuse upon contact and form syncytia in culture. HeLa is a human carcinoma cell line and HeLa-CD4 + contains in its genome CD4 DNA introduced by transfection, and it expresses CD4 antigen on its cell surface. The procedure used in the present studies is similar to that described (P.J. Madden et al., Cell 1986; 47:333-348). In essence, HeLa- CD4 + cells were plated onto wells of 24-well microculture plates at 1 x 10 5 cells per well. The plates were incubated for 36 hours and by this time, the monolayer epithelial cells were almost confluent. When 1 x 10 4 infected H9 cells were added to the sub-confluent HeLa-CD4 + cells, the cells formed contacts and fused, and by 8 hours multinucleated giant cells (syncytia) formed. Those syncytia with more than five nuclei could be easily identified and enumerated, providing quantitative measurement of syncytium formation. When the effects of purified E. cσ/i ' -expressed gClq- R on syncytium formation were studied, gClq-R at different concentrations as mixed with infected H9 cells and added to the HeLa-CD4 + cells. The final total volume of the culture medium per well was 1 ml. At the end of the 8-hour incubation at 37°C in 5 % CO 2 , the wells were washed with RPMI-1640 culture medium, fixed with methanol, air-dried, and stained with 0.1 % methylene blue in methanol. The cells were examined at lOOx magnification and the number of syncytia (of more than 5 nuclei) were determined in four randomly chosen fields and averaged. The percent inhibition of syncytium formation was calculated from the reduction in the number of syncytia in wells with gClq-R added as compared to the control. The results, shown in Fig. 4, demonstrate that recombinant gClq-R inhibits the fusion between HIV-lIIIB-infected H9 cells and CD4 + -HeLa cells with IC 50 of 21 μg/ml. Example 7: Binding of gClq-R to HIV-lIIIB-infected H9 Cells as Measured bv Flow Cvtometry The binding of purified E. coli expressed gClq-R to gpl20 expressed on the surface of HIV-lIIIB-infected H9 cells was analyzed by indirect immunofluorescence flow cytometry. Fifty microliters of infected cells at 10 x 10 6 cells/ml in PBSB (phosphate-buffered saline with 1 % bovine serum albumin at pH 7.4) was mixed with a serial concentration of purified E. coli expressed gClq-R for 30 minutes on ice. The cells were then washed once in the same buffer by centrifugation at 300 x g for 5 minutes. The cell pellet was then resuspended in 50 μl of the same buffer, and 50 μl of affinity purified rabbit anti-gClq-R at 5 μg/ml was added for reaction on ice for 30 minutes. The cells were then washed as before, and 50 μl of fluorescein conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories) at 1 :40 dilution was added, and incubated for another 30 minutes on ice. The cells were then washed, fixed in 1 % paraformaldehyde and then analyzed using a Coulter EPIC cell analyzer (Coulter Electronics, Hialeah, Florida). In the controls, only rabbit anti- gClq-R and/or fluorescein conjugated donkey anti-rabbit IgG were used. Specific cell staining was calculated by subtracting the percent cell binding of the test from that of the control which was arbitrarily set at 10%. Uninfected H9 cells were also tested as negative control for the binding studies. The results showed that recombinant gClq-R bound to HIV-lIIIB- infected H9 cells in a dose-dependent manner (Fig. 5), but not to uninfected H9 cells. Example 8: Effect of Clα on HIV-1 gp!20 Binding to gClα-R in ELISA To test whether the natural ligand Clq shares the same binding site for gClq-R as gpl20, the effect of Clq on the binding of HIV-1 gpl20 to gClq-R was studied by ELISA. Wells of Immulon 2 microtest plates were coated with 50 μl of 5 μg/ml purified E. coli expressed gClq-R in 0.1 M sodium acetate buffer and incubated overnight at room temperature. The wells were then blocked with 200 μl of a blocking/dilution buffer PBSTB for 1 hour at room temperature. After the wells were washed with PBST, 50 μl of baculovirus expressed HIV-IIIIB gp 120 at 0.2 μg/ml were added to each well in the presence or absence of serially diluted E. coli expressed gClq-R or purified Clq from human serum (Quidel, San Diego, California) in the blocking/dilution buffer, and the wells were incubated for another hour at room temperature and then washed. Fifty microliters of HRP conjugated monoclonal antibody BAT 123 at 1:2000 dilution in the blocking/dilution buffer was added to each well for 1 hour at room temperature. The plate was then washed, and peroxidase substrate solution added for color development as described above. Specific reactivity was obtained by subtracting the OD of test wells with gpl20 added from that of control wells without gpl20. The results are shown in Fig. 6, where the line marked with filled circles represents Clq and the line marked with filled squares represents gClq-R. Clq does not compete with the binding of gpl20 to gClq-R, whereas gClq-R does as expected. This result indicates that gpl20 binds to gClq-R at a site distinct from that for Clq, and they are mutually non- interfering. This is a very important finding because when gClq-R is administered into HIV-1 -infected individuals or people exposed to HIV-1, the abundant amount of Clq present in the blood will not interfere with gClq-R in binding to HIV-1 gpl20 on the virions or infected cells. Furthermore, the ability of gClq-R to bind both Clq and gpl20 simultaneously is significant and beneficial, because gClq-R may be able to mediate activation of the classical complement pathway to lyse HIV-1 virions and HIV-1 -infected cells. Example 9: Reactivity of HIV-1 gp!20 with Different Recombinant Constructs of gClq-R To locate the gClq-R binding site for HIV-1 gpl20, recombinant constructs of gClq-R of varying lengths were made for ELISA. Wells of Immulon 2 microtest plates were coated with 100 μl of purified £. coli expressed full-length gClq-R (1-209 a.a.), gClq-R (58-209 a.a.), gClq-R (1-94 a.a.), or gClq-R (95-209 a.a.) at 5 μg/ml in 0.1 M sodium acetate buffer (pH 6) and incubated overnight at room temperature. After the wells were treated with the blocking/dilution buffer PBSTB for 1 hour at room temperature and rinsed with PBST, 100 μl of serially diluted baculovirus expressed HIV-IIIIB gpl20 (American Biotechnologies, Inc.) (from 2 μg/ml to 0.016 μg/ml) was added to the corresponding wells in duplicate for reaction for 1 hour at room temperature. The wells were then washed as before. The bound gpl20 was detected by addition of 100 μl of HRP- conjugated monoclonal antibody BAT 123 at dilution of 1 :2000 for 1 hour at room temperature. The wells were then washed, and 200 μl of the peroxidase substrate solution was added to each well for color development for 30 minutes. The reaction was stopped by addition of 50 μl of 2 M H 2 SO 4 , and the OD was measured by a BioTek ELISA reader at 450 nm. Specific reactivity was obtained by subtracting the OD of test wells with gpl20 added from that of control wells without gpl20. The results are shown in Fig. 7, where the line marked with filled squares represents the full-length gClq-R (1-209 a.a), the line marked with filled circles represents gClq-R (58-209 a.a.), the line marked with filled triangles represents gClq-R (1-94 a.a.), and the line marked with filled inverted triangles represents gClq-R (95-209 a.a.). Gpl20 binds to gClq-R (1-209 a.a.), gClq-R (58-209 a.a.) and gClq-R (95-209 a.a.), but not to gClq-R (1-94 a.a.). The results thus suggest that the binding site on gClq- R to gpl20 resides in its C-terminal portion. This observation is consistent with the result as shown in Fig. 6 that the gpl20 binding site is distinct from that for Clq, which was mapped to the peptidic segment in the N- terminus of gClq-R as shown in SEQ ID NO.: 8 (B. Ghebrehiwet et al., J. Exp. Med. 1994; 179: 1809-1821). This peptidic segment is equivalent to the amino acid residue nos. 76-93 of SEQ ID NO.: 1. Example 10: Peptide Mapping of the Binding Domain for 99-12-1 on gClα-R To map the epitope for 99-12-1 binding on gClq-R, the Multipin Peptide Synthesis techniques was used (H.M. Geysen et al. , Science 1987; 235: 1184-1190). Forty-one 12-mer peptides encompassing the entire sequence of gClq-R (the consecutive peptides overlap each other by seven amino acids) were synthesized individually in a sequential manner on plastic pins in an array of a 96-well microtest plate. The peptide set was custom synthesized by Chiron Mimotopes PTY. LTD. , Clayton, Victoria, Australia. The procedure for epitope mapping using this multipin peptide system was similar to the manufacturer's instruction manual. Briefly, the pins were first treated with a pre-coat buffer containing 2% bovine serum albumin and 0.1 % Tween 20 in PBS for 1 hour at room temperature. Then the pins were inserted into the individual wells of 96-well microtest plate 38 containing antibody 99-12-1 in the pre-coat buffer at 2 μg/ml. The incubation was for 1 hour at room temperature. The pins were washed in PBST (3 rinses for every 10 minutes), and then incubated in the wells of a 96-well microtest plate containing 100 μl of HRP-conjugated goat anti- mouse IgG (Fc) (Jackson ImmunoResearch Laboratories) at a 1 :4,000 dilution for 1 hour at room temperature. After the pins were washed as before, the pins were put into wells containing peroxidase substrate solution of diammonium 2,2'-azino-bis [3-ethylbenzthiazoline-b-sulfonate] (ABTS) and H 2 O 2 (Kirkegaard & Perry Laboratories Inc., Gaithersburg, Maryland) for 30 minutes at room temperature for color reaction. The plate was read at 405 nm by a BioTek ELISA plate reader against a background absorption wavelength of 492 nm. Wells showing color development indicated reactivity of the gClq-R derived peptides in such wells with 99-12-1. The results of the epitope mapping show that 99-12-1 binds to the peptide of SEQ ID NO. : 2. To confirm the binding epitope of 99-12-1, the peptide LM12DN of SEQ ID NO. : 2 was tested for binding to 99-12-1 in ELISA. The peptide of SEQ ID NO. : 8 (peptide TD18EE) which was defined earlier as the binding site for Clq (B. Ghebrehiwet et al. , J. Exp. Med. 1994; 179: 1809- 1821) was used as a negative control. Peptides LM12DN and TD18EE were synthesized by an automated peptide synthesizer (Applied Biosystems, Inc. , Foster City, California), using the 9-fluorenylmethoxycarbonyl synthesis protocol as described by the manufacturer's manual. In the peptide ELISA, wells of Immulon 2 microtest plates were coated with 50 μl of the peptides LM12DN or TD18EE at 1 μg/ml and incubated overnight at room temperature. After the coating solution was removed by flicking the plate, 200 μl of PBSTB were added to each well to saturate the non¬ specific sites for 1 hour at room temperature. The wells were then washed with PBST. Fifty microliters of serially diluted 99-12-1 in PBSTB were added in duplicate to the wells for 1 hour at room temperature. The plate was washed again. Fifty microliters of HRP-conjugated goat anti-mouse IgG (Fc) (Jackson ImmunoResearch Laboratories) at a dilution of 1 :2,000 was added to each well for 1 hour at room temperature. After the wells were washed, peroxidase substrate was added for color reaction as described above. The plate was read at 450 nm by using an ELISA reader. Specific reactivity was obtained by subtracting the OD of test wells with 99- 12-1 added from that of the control wells. The results are shown in Fig. 8, where the line marked with filled squares represents the peptide LM12DN and the line marked with filled circles represents the peptide TD18EE. 99-12-1 binds to the peptide LM12DN (SEQ ID NO. : 2) in a dose-dependent manner, but not to the peptide TD18EE (SEQ ID NO. : 8). Example 11 : Competition of the Binding of HIV-1 gp!20 to gClq- R bv Anti-gClq-R Monoclonal Antibody 99-12-1 in ELISA Wells of Immulon 2 microtest plates were coated with 50 μl of 5 μg/ml purified E. coli expressed gClq-R in 0.1M sodium acetate buffer (pH 6) and incubated overnight at room temperature. The wells were then blocked with 200 μl of a blocking/dilution buffer PBSTB for 1 hour at room temperature, and then washed with PBST. Fifty microliters of baculovirus expressed HIV-IIIIB gpl20 at 0.2 μg/ml were added to each well in the presence or absence of serially diluted 99-12-1 in the blocking/dilution buffer, and the wells were incubated for another hour at room temperature and then washed. Fifty microliters of HRP conjugated monoclonal antibody BAT 123 at 1:2000 dilution in the blocking/dilution buffer was added to each well, followed by incubation for 1 hour at room temperature. The plate was then washed, and peroxidase substrate solution added for color development as before. The inhibition of the binding of gpl20 to gClq-R by 99-12-1 is calculated as the difference in OD between wells with or without 99-12-1. Fig. 9 shows that 99-12-1 inhibits the binding of gpl20 to gClq-R in a dose-dependent manner, suggesting that 99-12-1 binds to a site in gClq-R crucial for the interaction with gpl20. The site is mapped to SEQ ID NO. : 2 as described in Example 10. Example 12: Competition of gClα-R Binding to HIV-1 gp!20 bv Antibodies G3-299 and 6205 in ELISA In order to help identify the gClq-R binding site on HIV-1 gpl20, a competition ELISA was designed to examine the effects of various anti- HIV-1 gpl20 antibodies and recombinant soluble CD4 (rsCD4) on the binding of gpl20 to gClq-R. Wells of Immulon 2 microtest plates were coated with 50 μl of 5 μg/ml purified E. coli expressed gClq-R in 0.1 M sodium acetate buffer (pH 6) and incubated overnight at room temperature. The wells were then blocked with 200 μl of a blocking/dilution buffer PBSTB for 1 hour at room temperature. Fifty microliters of baculovirus expressed HIV-IIIIB gp 120 at 0.2 μg/ml was added to each well in the presence or absence of serially diluted anti-HIV-1 gpl20 antibodies or rsCD4 (Biogen, Boston, Massachusetts) in the blocking/dilution buffer, and the wells were incubated for another hour at room temperature. The anti-HIV-1 gpl20 antibodies tested included: murine monoclonal antibody G3-299 (to the C4 region (amino acid residue nos. of HXB2R strain: 423-437), as shown in SEQ ID NO. : 9), sheep anti-HIV-1 gpl20 C5 region antibody, 6205 (to the sequence of amino acid residue nos. of HXB2R strain: 497-511, as shown in SEQ ID NO. : 10), and BAT085 (to the V2 region of amino acid residue nos. of HXB2R strain: 169-183, as shown in SEQ ID NO. : 11). The properties of G3-299 and BAT085 were described previously (N.C. Sun et al., J. Virol. 1989; 63:3579-3585; M.S.C. Fung et al. , J. Virol. 1992; 66:848-856). Antibody 6205 was purchased from International Enzymes, Fallbrook, California. After the plate was washed, 50 μl of HRP conjugated monoclonal antibody BAT123 at 1 :2,000 dilution in the blocking/dilution buffer were added to each well, followed by incubation for 1 hour at room temperature. The plate was then washed, and peroxidase substrate solution added for color development as before. The percent inhibition of the binding of gpl20 to gClq-R by anti-HIV-1 gpl20 antibodies or rsCD4 is calculated as the difference in OD between wells with or without the competing agents. The results are shown in Fig. 10, where the line marked with solid circles represents anti-gpl20 C4 region G3-299, the line marked with solid squares represents polyclonal sheep anti-gpl20 C5 region, 6205, the line marked with solid triangles represents rsCD4. It can be seen that G3-299 competes very effectively the gpl20 binding to gClq-R, and moderately for 6205; whereas rsCD4 does not. The antibody BAT085 to the V2 region also does not inhibit the binding. Taken together, the results from Examples 4 and 12 indicate that the gClq-R Binding Site resides in the proximity of the C4 and C5 regions. It is distinct from the CD4 binding site. This important finding suggests that both gClq-R and rsCD4 can be applied in combination for treatment of HIV-1 infection. This may broaden the effectiveness of preventing the infection of both CD4-positive and CD4- negative target cells. Example 13: Peptide Mapping of the Binding Domain for gClq-R on HIV-1 gp!20 To determine the peptide epitope of gClq-R binding domain on HIV-1 gpl20, the Multipin Peptide Synthesis techniques were again used as described above. Ninety-four 12-mer peptides encompassing the entire sequence of HIV-IMN gpl20 (the consecutive peptides overlap each other by seven amino acids) were synthesized on plastic pins in an array for a 96- well microtest plate by Chiron Mimotopes Peptide Systems. The amino acid sequence of HIV-IMN gpl20 was based on the Los Alamos National Laboratory's database (G. Myers et al., Human Retroviruses and AIDS, 1992). The procedure for epitope mapping is similar to that set forth in Example 10 above. Purified E. coli expressed gClq-R at 5 μg/ml was used to react with the peptides on the plastic pins. After the pins were washed the bound gClq-R was detected by reaction with affinity purified rabbit anti-gClq-R immunoglobulin for 1 hour at room temperature. The pins were rinsed as before, and reacted with donkey anti-rabbit IgG conjugated with HRP (Jackson ImmunoResearch Laboratories). The procedure for color development was the same as before. Confirmation of the binding epitope of gClq-R on HIV-1 gpl20 was carried out by using overlapping synthetic peptides covering the binding region as coating antigen in ELISA. HIV-1 HXB2R gpl20 overlapping peptides RC16GG (amino acid residue nos. : 444-459, as shown in SEQ ID NO.: 3), RC12LT (amino acid residue nos. : 444-455, as shown SEQ ID NO.: 12), and TG12NN (amino acid residue nos. : 450-461, as shown SEQ ID NO. : 13) were purchased from American Biotechnologies, Inc. Wells of Immulon 2 microtest plates were coated with 100 μl of the corresponding peptides at 2 μg/ml for overnight at room temperature. The wells were then treated with 200 μl of a blocking/dilution buffer PBSTB for 1 hour at room temperature. The wells were then washed with PBST. Purified E. coli expressed gClq-R at different concentrations was added in duplicate to the wells for reaction for 1 hour at room temperature. The plates were then washed as before. One hundred microliters of affinity purified rabbit anti- gClq-R immunoglobulin at 2 μg/ml were added to each well for 1 hour at room temperature. The plate was then washed. One hundred microliters of diluted HRP conjugated donkey anti-rabbit IgG were added for another hour at room temperature, and the plate was washed. Peroxidase substrate solution was added as before for color development. The results are shown in Fig. 11, where the line marked with filled squares represents RC12LT, the line marked with filled circles represents TG12NN, and the line marked with filled triangles represents RC16GG. It can be seen that only RC16GG reacted with gClq-R. This result is consistent with the fact that the gClq-R binding site on gpl20 is located in the peptidic segment as shown in SEQ ID NO. : 3, which is located in the C4 region of gpl20. The antibody G3-299 can compete effectively the binding of gpl20 to gClq-R as shown in Example 12, probably because of the close proximity between the binding site of G3-299 (SEQ ID NO. : 9) and that of gClq-R (SEQ ID NO.: 3). It should be understood that the terms, expressions and examples set forth herein are exemplary only and not limiting, and that the scope of the invention is defined only by the claims which follow, and includes all equivalents of such claimed subject matter. Sequence Listing 1) General Information: i) Applicants: Fung, Michael S.C, Sun, Bill N.C, Sun, Cecily R.Y., Kim, Young . , Yu, Liming ii) Title of Invention: THE gClq RECEPTOR, HIV-1 gpl20 REGION BINDING THERETO, AND RELATED PEPTIDES AND TARGETING ANTIBODIES iii) Number of Sequences: 13 iv) Correspondence Address: A) Addressee: Tanox Biosystems, Inc. (B) Street: 10301 Stella Link Rd. C) City: Houston D) State: Texas E) Country: USA F) Zip: 77025 (v) Computer Readable Form: A) Medium Type: Diskette, 3.5 inch B) Computer: IBM PS/2 C) Operating System: DOS 3.30 D) Software: Wordperfect 5.1 (vi) Current application data: A) Application Number: B) Filing Date: C) Classification: vii) Prior Application Data: (A) Application Number: 08/410,360 B) Filing Date: 24/03/1995 viii) Attorney/Agent Information: A) Name: Mirabel, Eric P. B) Registration Number: 31,211 (C) Reference/Docket Number: TNX95-1-PCT ix) Telecommunication Information: A) Telephone: (713) 664-2288 B) Telefax: (713) 664-8914 2) Information for SEQ ID NO:l: (i) Sequence Characteristics: A) Length: 1138 nucleotides B) Type: nucleic acid C) Strandedness : double stranded D) Topology: linear (xi) Sequence Description: SEQ ID NO:l CCGGCGGCGC CTCAGGTCGC GGGGCGCCTA GGCCTGGGTT 40 GTCCTTTGCA TCTGCACGTG TTCGCAGTCG TTTCCGCG 78 ATG CTG CCT CTG CTG CGC TGC GTG CCC CGT GTG CTG GGC TCC TCC 123 Met Leu Pro Leu Leu Arg Cys Val Pro Arg Val Leu Gly Ser Ser 5 10 15 GTC GCC GGC CTC CGC GCT GCC GCG CCC GCC TCG CCT TTC CGG CAG 168 Val Ala Gly Leu Arg Ala Ala Ala Pro Ala Ser Pro Phe Arg Gin 20 25 30 CTC CTG CAG CCG GCA CCC CGG CTG TGC ACC CGG CCC TTC GGG CTG 213 Leu Leu Gin Pro Ala Pro Arg Leu Cys Thr Arg Pro Phe Gly Leu 35 40 45 CTC AGC GTG CGC GCA GGT TCC GAG CGG CGG CCG GGC CTC CTG CGG 258 Leu Ser Val Arg Ala Gly Ser Glu Arg Arg Pro Gly Leu Leu Arg 50 55 60 CCT CGC GGA CCC TGC GCC TGT GGC TGT GGC TGC GGC TCG CTG CAC 303 Pro Arg Gly Pro Cys Ala Cys Gly Cys Gly Cys Gly Ser Leu His 65 70 75 ACC GAC GGA GAC AAA GCT TTT GTT GAT TTC CTG AGT GAT GAA ATT 348 Thr Asp Gly Asp Lys Ala Phe Val Asp Phe Leu Ser Asp Glu lie 80 85 90 AAG GAG GAA AGA AAA ATT CAG AAG CAT AAA ACC CTC CCT AAG ATG 393 Lys Glu Glu Arg Lys lie Gin Lys His Lys Thr Leu Pro Lys Met 95 100 105 TCT GGA GGT TGG GAG CTG GAA CTG AAT GGG ACA GAA GCG AAA TTA 438 Ser Gly Gly Trp Glu Leu Glu Leu Asn Gly Thr Glu Ala Lys Leu 110 115 120 GTG CGG AAA GTT GCC GGG GAA AAA ATC ACG GTC ACT TTC AAC ATT 483 Val Arg Lys Val Ala Gly Glu Lys He Thr Val Thr Phe Asn He 125 130 135 AAC AAC AGC ATC CCA CCA ACA TTT GAT GGT GAG GAG GAA CCC TCG 528 Asn Asn Ser He Pro Pro Thr Phe Asp Gly Glu Glu Glu Pro Ser 140 145 150 CAA GGG CAG AAG GTT GAA GAA CAG GAG CCT GAA CTG ACA TCA ACT 573 Gin Gly Gin Lys Val Glu Glu Gin Glu Pro Glu Leu Thr Ser Thr 155 160 165 CCC AAT TTC GTG GTT GAA GTT ATA AAG AAT GAT GAT GGC AAG AAG 618 Pro Asn Phe Val Val Glu Val He Lys Asn Asp Asp Gly Lys Lys 170 175 180 GCC CTT GTG TTG GAC TGT CAT TAT CCA GAG GAT GAG GTT GGA CAA 663 Ala Leu Val Leu Asp Cys His Tyr Pro Glu Asp Glu Val Gly Gin 185 190 195 GAA GAC GAG GCT GAG AGT GAC ATC TTC TCT ATC AGG GAA GTT AGC 708 Glu Asp Glu Ala Glu Ser Asp He Phe Ser He Arg Glu Val Ser 200 205 210 TTT CAG TCC ACT GGC GAG TCT GAA TGG AAG GAT ACT AAT TAT ACA 753 Phe Gin Ser Thr Gly Glu Ser Glu Trp Lys Asp Thr Asn Tyr Thr 215 220 225 CTC AAC ACA GAT TCC TTG GAC TGG GCC TTA TAT GAC CAC CTA ATG 798 Leu Asn Thr Asp Ser Leu Asp Trp Ala Leu Tyr Asp His Leu Met 230 235 240 GAT TTC CTT GCC GAC CGA GGG GTG GAC AAC ACT TTT GCA GAT GAG 843 Asp Phe Leu Ala Asp Arg Gly Val Asp Asn Thr Phe Ala Asp Glu 245 250 255 CTG GTG GAG CTC AGC ACA GCC CTG GAG CAC CAG GAG TAC ATT ACT 888 Leu Val Glu Leu Ser Thr Ala Leu Glu His Gin Glu Tyr He Thr 260 265 270 TTT CTT GAA GAC CTC AAG AGT TTT GTC AAG AGC CAG 924 Phe Leu Glu Asp Leu Lys Ser Phe Val Lys Ser Gin 275 280 TAGAGCAGAC AGATGCTGAA AGCCATAGTT TCATGGCAGG 964 CTTTGGCCAG TGAACAAATC CTACTCTGAA GCTAGACATG 1004 TGCTTTGAAA TGATTATCAT CCTAATATCA TGGGGGAAAA 1044 AATACCAAAT TTAAATTATA TGTTTTGTGT TCTCATTTAT 1084 TATCATTTTT TTCTGTACAA TCTATTATTT CTAGATTTTT 1124 GTATAACATG ATAG 1138 (2) Information for SEQ ID NO: 2 : (i) Sequence Characteristics: (A) Length: 12 amino acids (B) Type: amino acid (D) Topology: linear (xi) Sequence Description: SEQ ID NO:2 Leu Met Asp Phe Leu Ala Asp Arg Gly Val Asp Asn 5 10 (2) Information for SEQ ID NO: 3 : (i) Sequence Characteristics: (A) Length: 16 amino acids (B) Type: amino acid (D) Topology: linear (xi) Sequence Description: SEQ ID NO: 3 Arg Cys Ser Ser Asn He Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly 5 10 15 (2) Information for SEQ ID NO : 4 (i) Sequence Characteristics: (A) Length: 26 nucleotides (B) Type: nucleic acid (C) Strandedness : double stranded (D) Topology: linear (xi) Sequence Description: SEQ ID NO:4 TACATATGCT GCACACCGAC GGAGAC 26 (2) Information for SEQ ID NO: 5: (i) Sequence Characteristics: (A) Length: 24 nucleotides (B) Type: nucleic acid (C) Strandedness: double stranded (D) Topology: linear (xi) Sequence Description: SEQ ID NO: 5 GCCCTGCAGC ATCTGTCTGC TCTA 24 (2) Information for SEQ ID NO:6: (i) Sequence Characteristics: (A) Length: 25 nucleotides (B) Type: nucleic acid (C) Strandedness: double stranded (D) Topology: linear (xi) Sequence Description: SEQ ID NO:6 AAGAATTCCG GTCACTTTCA ACATT 25 (2) Information for SEQ ID NO:7: (i) Sequence Characteristics: (A) Length: 15 amino acids (B) Type: amino acid (D) Topology: linear (xi) Sequence Description: SEQ ID NO:7 Arg He Gin Arg Gly Pro Gly Arg Ala Phe Val Thr He Gly Lys 5 10 15 (2) Information for SEQ ID NO:8: (i) Sequence Characteristics: (A) Length: 18 amino acids (B) Type: amino acid (D) Topology: linear (xi) Sequence Description: SEQ ID NO:8 Thr Asp Gly Asp Lys Ala Phe Val Asp Phe Leu Ser Asp Glu He Lys Glu Glu 5 10 15 (2) Information for SEQ ID NO: 9 : (i) Sequence Characteristics: (A) Length: 15 amino acids (B) Type: amino acid (D) Topology: linear (xi) Sequence Description: SEQ ID NO: 9 He He Asn Met Trp Gin Lys Val Gly Lys Ala Met Tyr Ala Pro 5 10 15 (2) Information for SEQ ID NO: 10: (i) Sequence Characteristics: (A) Length: 15 amino acids (B) Type: amino acid (D) Topology: linear (xi) Sequence Description: SEQ ID NO:10 Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gin Arg Glu Lys Arg 5 10 15 (2) Information for SEQ ID NO: 11: (i) Sequence Characteristics: (A) Length: 15 amino acids (B) Type: amino acid (D) Topology: linear (xi) Sequence Description: SEQ ID NO:11 Val Gin Lys Glu Tyr Ala Phe Phe Tyr Lys Leu Asp He He Pro 5 10 15 (2) Information for SEQ ID NO:12: (i) Sequence Characteristics: (A) Length: 12 amino acids (B) Type: amino acid (D) Topology: linear (xi) Sequence Description: SEQ ID NO:12 Arg Cys Ser Ser Asn He Thr Gly Leu Leu Leu Thr 5 10 (2) Information for SEQ ID NO:13: (i) Sequence Characteristics: (A) Length: 12 amino acids (B) Type: amino acid (D) Topology: linear (xi) Sequence Description: SEQ ID NO:13 Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Asn Asn 5 10

Claims: What Is Claimed Is: 1. A peptide having the sequence of SEQ ID NO: 2. 2. The peptide of claim 1 conjugated with a carrier which increases its immunogenicity. 3. The peptide of claim 2 wherein the carrier is KLH. 5 4. An oligonucleotide coding for the peptide of SEQ ID NO: 2. 5. The oligonucleotide of claim 4 which is a deoxyribonucleotide. 6. Binding molecules or antibodies which target the peptide of claim 1. 7. The binding molecules or antibodies of claim 6 which are monoclonal antibodies. 8. The monoclonal antibody 99-12-1. 10 9. The cell line producing the monoclonal antibody 99-12-1. 10. A peptide having the sequence of SEQ ID NO. : 3. 11. The peptide of claim 10 conjugated with a carrier which increases its immunogenicity. 12. The peptide of claim 10 wherein the carrier is KLH. 15 13. An oligonucleotide coding for the peptide of SEQ ID NO. : 3. 14. The oligonucleotide of claim 13 which is a deoxyribonucleotide.

Inventors: FUNG MICHAEL S C, KIM YOUNG WOO, SUN BILL N C, SUN CECILY R Y, YU LIMING, FUNG, MICHAEL, S., C., KIM, YOUNG, WOO, SUN, BILL, N., C., SUN, CECILY, R., Y., YU, LIMING
Applicants: TANOX BIOSYSTEMS INC, TANOX BIOSYSTEMS, INC.
Application year: 1996
Main classification: C07K7
IPC codes: A61K38, C07K14, C07K16, C12N5, C12N15, C12P21, C12R1